The solid-state structures of the salts of three psilacetin derivatives, namely, 4-acetoxy- N -ethyl- N -methyltryptammonium (4-AcO-MET) hydrofumarate {systematic name: [2-(4-acetyloxy-1 H -indol-3-yl)ethyl](methyl)ethylazanium 3-carboxyprop-2-enoate}, C 15 H 21 N 2 O 2 + ·C 4 H 3 O 4 − , 4-acetoxy- N -allyl- N -methyltryptammonium (4-AcO-MALT) hydrofumarate {systematic name: [2-(4-acetyloxy-1...
Patients with major depressive disorder who received two administrations of the psychedelic psilocybin as part of a psychotherapy regimen saw a rapid and lasting improvement in depression symptoms, a randomized open‐label trial has found. These findings extend results of research that have suggested antidepressant effects for psilocybin in patients with cancer and treatment‐resistant...
Major depressive disorder (MDD) has become a health crisis of epidemic proportions in the modern world. One in six individuals in the world is experiencing an episode of major depression in his or her lifetime, and it is estimated that major depression will rank second after cardiac disease as a cause of international medical morbidity by the year 2020. Depression is associated with greater...
Psilocybin therapy appears to be at least as effective as escitalopram in treating depression, findings from a small phase II study published in the New England Journal of Medicine have indicated (15 April 2021)[1]. Researchers compared two sessions of psychedelic psilocybin therapy, delivered in a specialist clinical setting, with a course of the selective serotonin […]
Brazilian Journal of Development2021Vagner Fagnani Linartevichi, Matheus Gonzales Froza, Rafael de Morais Cury et al.4 citations
A depressão, ou Distúrbio Depressivo Maior (DDM), é uma enfermidade que acomete cerca de 322 milhões de pessoas e pode ser debilitante, havendo uma grande demanda para tratamentos eficazes no manejo desta doença. O presente estudo teve por objetivo organizar uma revisão de artigos publicados acerca do uso do composto psilocibina, a fim de averiguar seu potencial terapêutico no tratamento de...
Psilocybin, a drug most commonly recognized as a recreational psychedelic, is quickly gaining attention as a promising therapy for an expanding range of neurological conditions, including depression, anxiety, and addiction. This growing interest has led to many recent advancements in psilocybin synthesis strategies, including multiple in vivo fermentation-based approaches catalyzed by...
Abstract Background: Psilocybin is a predominant agonist of 5HT 1A and 5HT 2A/C receptors and was first isolated in 1958, shortly before it became a controlled substance. Research on the potential therapeutic effects of this compound has recently re-emerged alongside what is being addressed as a psychedelic renaissance. Methods: In this paper we performed a systematic review of the clinical...
Since a 1957 exposé in Life Magazine, chemical compounds derived from Psilocybe mushrooms have been the focus of dozens of attempted and successful patents, most recently to treat depression. Regrettably, the Mazatec indigenous communities who stewarded these traditional medicines for millenia are not party to any of these patents, despite a number of international treaties asserting indigenous...
While anecdotal evidence suggests that select 5-hydroxytryptamine 2A (5-HT2A) receptor ligands, including psilocybin, may have long-lasting therapeutic effects after limited dosing in headache disorders, controlled investigations are lacking. In an exploratory double-blind, placebo-controlled, cross-over study, adults with migraine received oral placebo and psilocybin (0.143 mg/kg) in 2 test...